Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

During pregnancy, 12 women who smoked more than 10 cigarettes/day and 12 nonsmokers had blood taken and analyzed at 12, 20, 25, 30, 34, and 38 weeks of gestation. Fibrinogen, plasminogen, plasminogen activator, serum fibrin degradation products, antithrombin 3, alpha 1 antitrypsin, and alpha 2 macroglobulin were measured. The only significant (p .05) difference was that plasma fibrinogen was lower among smokers at 20 weeks. However, there were other patterns of difference -- mean fibrinogen and plasminogen levels were slightly lower throughout pregnancy and reached a lower peak in the smoking group. Fibrinolytic activity fell in the smokers to the same low level as in nonsmokers by 38 weeks, but at a slower rate. Serum fibrin degradation products and alpha 2 macroglobulin were consistently higher in the smoking group. Although the findings showed no major disseminated intravascular coagulation in smokers, there was a pattern of a possible low-grade syndrome.
 ...
PMID:The influence of smoking on the haemostatic mechanism in pregnancy. 6 96

An activator of plasminogen with specific activity 203 AU/mg was isolated from blood plasma with fibrinolytic activity, obtained from blood of suddenly decreased patients. Specific activity of the plasminogen activator exceeded 88-fold the activity of the initial blood plasma. The protein was identified with a glycoprotein, similar to beta-globulin; its molecular weight was 70,000 as shown by gel filtration; the isoelectric point was at pH 6.2. The plasminogen activator remained stable after heating up to 50 degrees. Effects of pH in an incubation media and of cations on the activity of the plasminogen activator were studied. A fraction containing the fibrinolytic activity and enriched with plasminogen activator was obtained from the blood plasma after fractionation at low temperature with ethanol at definite pH value. The specific fibrinolytic activity in the fraction exceeded 17.6-fold the activity of blood plasma. The fraction exhibited high thrombolytic and antithrombin activities in vitro. It was similar to streptase and streptokinase preparations in its throm-bolytic effect. Relative species specificity was found in studies of the fibrinolytic and antithrombin effects of the fraction containing fibrinolytic activity.
 ...
PMID:[Characteristics of human plasminogen activator and of a fraction of fibrinolytically active plasma enriched with this enzyme]. 15 62

The saliva of the tsetse, Glossina morsitans morsitans Westwood, has antithrombin anticoagulant activity and inhibits thrombin's esterolytic activity. It has no other detectable anticoagulant properties. The anticoagulant elutes in a single peak on Sephadex fraction, is immediately acting, heat and storage stable, and has a molecular weight of 11-13,000. Unlike heparin it is not neutralized by protamine sulphate or toluidine blue and does not require the co-factor, antithrombin III, for optimal anticoagulant activity. It has similar properties to hirudin, but does not elute with a protein peak upon Sephadex fractionation and has a slightly different molecular weight. Salivary gland homogenates contained neither a plasminogen activator nor fibrinolytic activity. The sera of rabbits used to maintain tsetses, which contained precipitating antibodies against saliva, did not neutralize the salivary anticoagulant in vitro. The properties of this anticoagulant suggest that it might be a potentially useful antithrombotic agent in man.
 ...
PMID:Effects of tsetse (Glossina morsitans morsitans Westw.) (Diptera: Glossinidae) salivary gland homogenate on coagulation and fibrinolysis. 50 76

Lysates of leukocytes of healthy persons and of patients with acute and chronic leukemias possess a weak tissue factor activity. This procoagulant activity is increased greatly when leukocytes are stimulated by endotoxin. The tissue factor is derived almost exclusively from the monocytes and not from lymphocytes and granulocytes. Monocytes are stimulated to the same extent by adherence to plastic surfaces. The fibrinolytic activity of lysates of mixed leukocytes is due to a nonspecific protease and a plasminogen activator. Only granulocytes can cause fibrinolyses. Endotoxin stimulation enhances the plasminogen activator but not the protease. Normal leukocytes and leukocytes of patients with chronic leukemias also exert an antithrombin activity.
 ...
PMID:[Effect of normal and leukemic leukocytes on blood coagulation and fibrinolysis]. 65 68

The Hageman factor dependent pathways are influenced by several control proteins which modulate the extent of activation and biologic activity of these enzyme substrates (Fig. 1). C1 INH plays a prominent role by acting at the common initiating step for all three Hageman factor dependent systems and its deficiency produces disease in man. Alpha-2 macroglobulin appears to play an important role in the fibrinolytic sequence, having potent activity towards both plasminogen activator and plasmin. Antithrombin most prominently influences the state of activation of the coagulation sequence by regulating the enzymatic activities of activated Factors XI, IX and X and, most importantly, that of thrombin. Significantly, deficiency of antithrombin results in increased thrombosis in man.
 ...
PMID:Plasma inhibitors of the Hageman factor dependent pathways. 79 48

During one year experiment, the thromboplastic, antiheparin, plasminogen activator, antithrombin and antiplasmin activities were evaluated in the homogenates of the intimal, medial and adventitial layers of polyester double velour DALLON prostheses implanted into the dog abdominal aorta. It was found, that 7 days after implantation the thromboplastic, antiheparin and plasminogen activator activities in DALLON graft neointima were high, whereas those of the antiplasmin and antithrombin were low. These changes facilitate the sealing of the prosthesis pores and at the same time prevents thrombosis. Four months after implanting, the activity of hemostatically active components in the various graft layers became similar to the activity of aorta components. Rapid decrease of the thrombogenic potential and increase of the fibrinolytic activity in layers of double velour DALLON grafts facilitate the maintenance of graft patency.
 ...
PMID:[Changes in the activity of the clotting system and fibrinolysis components in the layers of double velour DALLON grafts at different periods after implantation into the aorta]. 130 65

Thrombolysis during the early hours of a myocardial infarction significantly improves patient survival in a hospital. Beyond 6 hours, up to 24 hours, thrombolysis may still contribute to a reduction in mortality. However, further confirmation is desirable before such therapy late in the course of an evolving infarct can be routinely recommended. Although clot-specific agents such as recombinant tissue-type plasminogen activator (rt-PA) produce a higher initial patency rate, reocclusion rates are higher in the absence of the profound systemic fibrinolysis produced by agents such as streptokinase. This may explain the GISSI-2 results where 15-day survival was no different between the streptokinase- and rt-PA-treated subjects. Although the manner of heparin administration may have clouded these results, current research is directed toward looking at combinations of thrombolytic agents that would combine drugs efficient in producing early patency with those that produce a more pronounced fibrinolytic state. More effective adjunctive therapy is also under intense investigation, particularly specific antithrombin agents that would produce more effective anticoagulation following thrombolysis, and more effective antiplatelet agents that would help prevent reocclusion.
 ...
PMID:Thrombolytic therapy for myocardial ischemia and infarction. 134 5

Thrombus formation in anesthetized, open-chest dogs was induced by electrical injury to the intimal surface of the left circumflex coronary artery. One-hour postocclusion, administration of vehicle to heparinized dogs (n = 12) did not induce reperfusion despite concomitant treatment with acetylsalicylic acid (ASA), sulotroban, or saline. Intravenous bolus injection of 140 kU/kg (= 0.24 mg/kg) of the unglycosylated t-PA variant BM 06.022 induced reperfusion in 4 out of 6 dogs, followed by flow deterioration. Pretreatment with i.v. ASA did not improve coronary blood flow (CBF). Conjunctive treatment with the thromboxane A2-receptor antagonist, sulotroban, (10 mg/kg i.v. bolus, followed by 10 mg/kg/h) or with recombinant hirudin, a specific thrombin inhibitor, (1 mg/kg/h) 30 min prior to i.v. injection of BM 06.022, prolonged (p < 0.01) the cumulative patency time (sum of time-intervals in which the coronary artery was patent) to 147.4 +/- 9.2 min in 4 out of 6 reperfused dogs and 129.9 +/- 12.3 min in 7 out of 8 dogs, respectively, compared to the saline plus BM 06.022 treatment (47.5 +/- 13.1 min) in 4 out of 6 dogs. The terminal CBF was higher (p < 0.01) after sulotroban plus BM 06.022 (7.0 +/- 1.7 ml/min) and hirudin plus BM 06.022 (6.3 +/- 1.5 ml/min) than after saline plus BM 06.022 (0.8 ml/min). These findings demonstrate that drugs with antithromboxane or antithrombin activity may improve CBF after reperfusion.
 ...
PMID:Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis. 142 Nov 76

The objective of the study was to investigate the acute effect of a single very high dose of n-3 PUFA on coagulation and fibrinolysis. Forty healthy volunteers were randomized into two groups to receive either 20 grams of n-3 PUFA or 20 grams of n-6 PUFA as a single dose at 6 p.m. with their evening meal. Coagulation and fibrinolysis were evaluated in the fasting state at 8 a.m. the next morning and compared to values obtained at 8 a.m. the day before, when the participants were on their habitual diets. PAI-1 activity in plasma increased by a mean of 62% in subjects randomized to receive n-3 PUFA despite that no changes could be demonstrated in t-PA antigen levels. PAI-1 activity was unaltered in the 20 controls receiving n-6 PUFA. Plasma fibrinogen, coagulation factor VII, thrombin-antithrombin complexes and D-dimer did not significantly change after either supplement. The substantial increase in levels of PAI-1 activity in plasma after a single very high dose of n-3 PUFA may limit the usefulness of single very high doses of n-3 PUFA in acute clinical conditions.
 ...
PMID:The acute effect of a single very high dose of N-3 fatty acids on coagulation and fibrinolysis. 144 89

In the present study we investigated several factors of hemostasis and fibrinolysis during the normal pregnancy in 52 women. Whereas the Thrombin-Time did not show any change, the increase of the Hepato-Quick and the decrease of the Partial Thromboplastin-Time was significant. During pregnancy we observed a significant increase of the activity of fibrinogen, factor XII and prekallikrein as well as of the von-Willebrand-factor-antigen (VIIIR:Ag). The activity of factor II and X remained constantly. The increased activity of factors of hemostasis was accompanied by an increase of activity and concentration of antithrombin-III. In contrast to the activity of the hemostatic system we could not find any significant alteration of the fibrinolytic system. The cause must be searched in the observed increase of plasminogen-activator-inhibitor (PAI)--likly in combination with a decrease of the tissue-type plasminogen activator (t-PA). Our data indicate, that the highest risk for thrombosis already might exist in week 24 of pregnancy, because a distinct increase of hemostatic activity is combined with a nearly unchanged fibrinolytic activity.
 ...
PMID:[Changes in the blood coagulation and fibrinolysis system in the course of normal pregnancy]. 162 53


1 2 3 4 5 6 7 8 9 10 Next >>